The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The cost implications of prostate cancer screening in the Medicare population.
Xiaomei Ma
No relevant relationships to disclose
Rong Wang
No relevant relationships to disclose
Jessica B. Long
No relevant relationships to disclose
Joseph S. Ross
Consultant or Advisory Role - Fair Health, Inc.
Research Funding - Medtronic
Pamela R. Soulos
No relevant relationships to disclose
James B. Yu
No relevant relationships to disclose
Danil V. Makarov
No relevant relationships to disclose
Heather Taffet Gold
No relevant relationships to disclose
Cary Philip Gross
Consultant or Advisory Role - Fair Health, Inc.
Research Funding - Medtronic